ArticleWorld journal of surgical oncology2026
Risk evaluation for second primary malignancy development in individuals with colorectal adenocarcinoma: a population-based investigation.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndividuals diagnosed with primary colorectal adenocarcinoma (CRA) face an elevated likelihood of developing second primary malignancies (SPMs). This study aimed to develop and validate prognostic nomograms for these patients to aid personalized follow-up and treatment planning.
methodsWe retrieved clinical data of patients diagnosed with primary CRA between 2004 and 2020 from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were divided into only one primary malignancy (OOPM) and SPM group. The SPM cohort was randomly divided into training (70%) and validation (30%) sets. A Cox regression model identified independent prognostic factors, which were incorporated into a nomogram to predict 3-, 5-, and 10-year overall survival (OS). The model’s performance was evaluated using the concordance index (C-index), calibration plots, ROC curves, and decision curve analysis (DCA).
resultsAmong 187,204 patients with CRA, 18,668 (9.97%) developed SPMs. The most common SPM sites were the prostate, lung/bronchi, and colon in males and the breast, colon, and lung/bronchi in females. The final nomogram incorporated ten variables: age, sex, marital status, tumor size, primary tumor surgery, chemotherapy, and disease stage information (SEER stage, T, and N stages). The model demonstrated moderate discriminative ability, with C-indices of 0.635 and 0.634 in the training and validation sets, respectively. Calibration and DCA indicated good agreement between predicted and observed outcomes and clinical utility.
conclusionWe present a nomogram that offers individualized survival estimates for CRA patients with SPMs. While further validation is warranted, this tool shows potential for improving risk assessment and supporting clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.